Literature DB >> 16227347

Role of nitric oxide and prostanoids in attenuation of rapid baroreceptor resetting.

Maria Cristina O Salgado1, Soraia V S Justo, Luis F Joaquim, Rubens Fazan, Helio C Salgado.   

Abstract

Because the regulation of vascular function involves complex mutual interactions between nitric oxide (NO) synthase (NOS) and cyclooxygenase (COX) products, we examined the contribution of NO and prostanoids derived from the COX pathway in modulating aortic baroreceptor resetting during an acute (30 min) increase in arterial pressure in anesthetized rats. Increase in pressure was induced either by administration of the nonselective NOS inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME) or aortic coarctation (COA) with or without treatment with the COX inhibitor indomethacin (INDO) or the selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)imidazole (TRIM). The activity of the aortic depressor nerve and arterial pressure were simultaneously recorded, and the degree of resetting was determined by the shift of the pressure-nerve activity curve using the ratio [delta systolic pressure at 50% of maximum baroreceptor activity/delta systolic pressure] x 100. The magnitude of pressure rise was similar in the different groups (59 +/- 6, 53 +/- 5, 53 +/- 5, 45 +/- 5, 49 +/- 3, and 41 +/- 3 mmHg for COA, L-NAME, INDO+COA, INDO+L-NAME, TRIM+COA, and TRIM+INDO+COA, respectively, P = 0.27). The degree of resetting that occurred with L-NAME or COA combined with treatment with TRIM was attenuated compared with COA alone (7 +/- 4, 5 +/- 2, and 31 +/- 6%, respectively, P = 0.04). INDO failed to influence baroreceptor resetting to higher pressure but prevented L-NAME- and TRIM-induced effects (20 +/- 7, 21 +/- 8, and 32 +/- 6% for INDO+COA, INDO+L-NAME, and INDO+TRIM+COA, respectively; P = 0.38). Baroreceptor gain was affected only by l-NAME. These findings indicate that NO, probably from neuronal origin, may exert stimulatory influence on the degree of rapid baroreceptor resetting to hypertension that involves COX-derived prostanoids.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227347     DOI: 10.1152/ajpheart.00219.2005

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  6 in total

1.  Baroreflex stimulation attenuates central but not peripheral inflammation in conscious endotoxemic rats.

Authors:  Fernanda Brognara; Jaci A Castania; Daniel P M Dias; Alexandre H Lopes; Rubens Fazan; Alexandre Kanashiro; Luis Ulloa; Helio C Salgado
Journal:  Brain Res       Date:  2018-01-06       Impact factor: 3.252

2.  Autocrine/paracrine modulation of baroreceptor activity after antidromic stimulation of aortic depressor nerve in vivo.

Authors:  Valter J Santana-Filho; Greg J Davis; Jaci A Castania; Xiuying Ma; Helio C Salgado; Francois M Abboud; Rubens Fazan; Mark W Chapleau
Journal:  Auton Neurosci       Date:  2014-02       Impact factor: 3.145

Review 3.  Central modulation of cyclosporine-induced hypertension.

Authors:  Hanan M El-Gowelli; Mahmoud M El-Mas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-11-29       Impact factor: 3.000

4.  Aliskiren and l-arginine treatments restore depressed baroreflex sensitivity and decrease oxidative stress in renovascular hypertension rats.

Authors:  Vinicius Mengal; Paulo Hm Silva; Renata V Tiradentes; Cintia H Santuzzi; Simone A de Almeida; Gabriela C Sena; Nazare S Bissoli; Glaucia R Abreu; Sonia A Gouvea
Journal:  Hypertens Res       Date:  2016-07-07       Impact factor: 3.872

5.  α-lipoic acid reduces hypertension and increases baroreflex sensitivity in renovascular hypertensive rats.

Authors:  Thyago M Queiroz; Drielle D Guimarães; Leônidas G Mendes-Junior; Valdir A Braga
Journal:  Molecules       Date:  2012-11-09       Impact factor: 4.411

6.  The Role of Nitric Oxide in the Efficacy of Adenosine, Lidocaine, and Magnesium Treatment for Experimental Hemorrhagic Shock in Rats.

Authors:  Hayley L Letson; Geoffrey P Dobson
Journal:  Curr Ther Res Clin Exp       Date:  2021-11-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.